You don’t need insurance to afford semaglutide for weight loss in Fon du Lac!
Have you been struggling to lose weight? Feel like you’ve tried everything and just don’t get the results you’re looking for? If you’re struggling with obesity or chronic weight-management issues, Forum Health Fon du Lac can help!
Semaglutide, a drug originally developed to treat Type 2 Diabetes, is changing the way people approach weight loss. It was discovered that when administered at higher doses, people had a mean weight loss of 14.9 percent! Semaglutide works by mimicking hormones in the body that are responsible for increasing insulin secretion and, at higher doses, suppresses appetite thus helping people lose more weight.
How Forum Health Fon du Lac is making semaglutide for weight loss accessible.
The problem until now has been that semaglutide is simply not affordable. Insurance companies will not cover semaglutide for weight loss, sold under the brand names: Ozempic, Rybelsus and Wegovy. And without insurance, semaglutide retails at more than $1,000!
Forum Health has developed an alternative to offer this life-changing drug at a fraction of the cost and with added support to make sure you succeed in losing the weight and keeping it off – The Forum Health Semaglutide Weight Loss Program!
As part of this program, Forum Health Fon du Lac is able to offer a generic version of semaglutide made at a compounding pharmacy, thus eliminating big brand-name costs. Additionally, we offer you value in the form of health-coach visits, body analysis, and lifestyle change recommendations.
Being at a healthy weight is important for long-term health and reduces the risk of cardiovascular disease, diabetes, osteoarthritis, sleep apnea, and related diseases.
Forum Health does not accept insurance or Medicare for the Semaglutide weight loss program. Semaglutide is FDA approved for weight loss and its effectiveness has been proven.
For more information on the Forum Health Semaglutide weight loss program and to see if it’s right for you, Contact us.
